📊 PLRX Key Takeaways
Is Pliant Therapeutics, Inc.. (PLRX) a Good Investment?
Pliant Therapeutics exhibits a reasonably healthy balance sheet with strong liquidity and zero debt, but faces critical execution risk as a pre-revenue pharmaceutical company burning approximately $19.2M annually with only ~1.2 years of cash runway. Success depends entirely on clinical development progress and future financing or revenue generation.
Pliant Therapeutics, Inc.. Key Strengths (PLRX)
- Strong balance sheet with $165.2M stockholders' equity and minimal liabilities of $37.4M
- Excellent liquidity position with 16.89x current ratio and $22.2M cash reserves; zero long-term debt
- Improving EPS metrics year-over-year (+30%) suggests better operational efficiency or reduced share dilution
PLRX Stock Risks: Pliant Therapeutics, Inc.. Investment Risks
- Limited cash runway of approximately 1.2 years at current burn rate of $19.2M annually
- Zero revenue indicates pre-commercialization stage with no validated business model or clinical success achieved
- Negative operating cash flow will likely require significant future capital raises, creating substantial shareholder dilution risk
Key Metrics to Watch
- Quarterly cash burn rate and remaining months of cash runway; trajectory of operating cash flow
- Clinical trial progress and regulatory milestones for pharmaceutical pipeline programs
- Capital structure changes including equity or debt financing announcements
Pliant Therapeutics, Inc.. (PLRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 16.89x current ratio provides a solid financial cushion.
PLRX Profit Margin, ROE & Profitability Analysis
PLRX vs Healthcare Sector: How Pliant Therapeutics, Inc.. Compares
How Pliant Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Pliant Therapeutics, Inc.. Stock Overvalued? PLRX Valuation Analysis 2026
Based on fundamental analysis, Pliant Therapeutics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Pliant Therapeutics, Inc.. Balance Sheet: PLRX Debt, Cash & Liquidity
PLRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Pliant Therapeutics, Inc..'s revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $-3.47 indicates the company is currently unprofitable.
PLRX Revenue Growth, EPS Growth & YoY Performance
PLRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | N/A | -$37.5M | $-0.70 |
| Q2 2024 | N/A | -$37.5M | $-0.70 |
| Q1 2024 | N/A | -$37.5M | $-0.67 |
| Q3 2023 | N/A | -$28.1M | $-0.65 |
| Q2 2023 | $248.0K | -$28.1M | $-0.70 |
| Q1 2023 | $1.2M | -$28.1M | $-0.67 |
| Q3 2022 | $1.5M | -$22.8M | $-0.65 |
| Q2 2022 | $1.8M | -$22.8M | $-0.64 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Pliant Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
PLRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Pliant Therapeutics, Inc.. (CIK: 0001746473)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PLRX
What is the AI rating for PLRX?
Pliant Therapeutics, Inc.. (PLRX) has an AI grade of B with 70% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PLRX's key strengths?
Claude: Strong balance sheet with $165.2M stockholders' equity and minimal liabilities of $37.4M. Excellent liquidity position with 16.89x current ratio and $22.2M cash reserves; zero long-term debt.
What are the risks of investing in PLRX?
Claude: Limited cash runway of approximately 1.2 years at current burn rate of $19.2M annually. Zero revenue indicates pre-commercialization stage with no validated business model or clinical success achieved.
What is PLRX's revenue and growth?
Pliant Therapeutics, Inc.. reported revenue of $0.0.
Does PLRX pay dividends?
Pliant Therapeutics, Inc.. does not currently pay dividends.
Where can I find PLRX SEC filings?
Official SEC filings for Pliant Therapeutics, Inc.. (CIK: 0001746473) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PLRX's EPS?
Pliant Therapeutics, Inc.. has a diluted EPS of $-0.32.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PLRX's fundamental grade?
Based on our AI fundamental analysis in May 2026, Pliant Therapeutics, Inc.. has a B grade with 70% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PLRX stock overvalued or undervalued?
Valuation metrics for PLRX: ROE of -12.1% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PLRX's AI grade for 2026?
Our dual AI analysis gives Pliant Therapeutics, Inc.. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PLRX's free cash flow?
Pliant Therapeutics, Inc..'s operating cash flow is $-19.2M, with capital expenditures of $0.0.
How does PLRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -12.1% (avg: 15%), current ratio 16.89 (avg: 2).